 |
|
|
|
prIME Oncology invites you to view exciting news released from the 2010 Oncology Annual Meeting
in Chicago.
|
|
|
 |
|
13 JUNE 2010
|
| |
|
This expert interview with Evangelos Terpos, MD, PhD, from the University of Athens School of Medicine, Athens, Greece, and Gareth Morgan, MD, PhD, from Royal Marsden Hospital in Surrey, United Kingdom, along with a special eNewsflash and downloadable slides, discusses the topic of the anticancer effects of bisphosphonates in multiple myeloma focusing on the following data release:
#8021: Evaluating the effects of zoledronic acid (ZOL) on overall survival (OS) in patients (Pts) with multiple myeloma (MM): Results of the Medical Research Council (MRC) Myeloma IX study
|
| |
|
|
| |
|
View the expert interview and opinion with Evangelos Terpos, MD, PhD, and Gareth Morgan, MD, PhD, and access the downloadable slides 
View eNewsflash
|
|
|
8 JUNE 2010
|
| |
|
#6501: Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year
The first interview is an expert review of the data with Andreas Hochhaus, MD, from the Universitätsklinikim Jena in Jena, Germany, and Lee Lokey, MD, from prIME Oncology in Atlanta, Georgia, United States
View the Expert Review of the data with Andreas Hochhaus, MD, and Lee Lokey, MD, and access the
downloadable slides
The second interview is an expert analysis and discussion of clinical implications with Richard Larson, MD, from the University of Chicago Medical Center in Chicago, Illinois, United States, and Lee Lokey, MD, from prIME Oncology in Atlanta, Georgia, United States.
View the Expert Analysis with Richard Larson, MD, and Lee Lokey, MD, and access the
downloadable slides
View eNewsflash
|
|
|
7 JUNE 2010
|
| |
|
This expert interview with Kenneth Anderson, MD, and Paul Richardson, MD, from the Dana-Farber Cancer Institute, Boston, Massachusetts, United States, along with a special eNewsflash and downloadable slides, discusses the topic of HDAC inhibitors in multiple myeloma focusing on the following data release:
#8001: Phase Ib study of oral panobinostat (LBH589) plus intravenous bortezomib in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM)
|
| |
|
View an expert interview and opinion with Kenneth Anderson, MD, and Paul Richardson, MD, and access
the downloadable slides
View eNewsflash
|
| |
|
|
| |
|
This expert interview with Michel Attal, MD, from Centre Hospitalier de Purpan, Toulouse, France; Philip McCarthy, Jr, MD, from Roswell Park Cancer Institute, Buffalo, New York, United States; and Kenneth Anderson, MD,
from the Dana-Farber Cancer Institute, Boston, Massachusetts, United
States, discusses the topic of newly released data concerning the role
of IMiDs in maintenance therapy for multiple myeloma. An eNewsflash and downloadable slide deck are also available focusing on the following data releases:
#8017:
Phase III intergroup study of lenalidomide versus placebo maintenance
therapy following single autologous stem cell transplant (ASCT) for
multiple myeloma (MM): CALGB 100104
#8018: Lenalidomide maintenance after transplantation for myeloma |
| |
|
View
the expert interview and opinion with Michel Attal, MD, Philip
McCarthy, Jr, MD, and Kenneth Anderson, MD, and access
the downloadable
slides
View eNewsflash |
|
|
|
|
|
|
|
|
|
|
|
|
